https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49619 2 GI tract areas are involved, the name should reflect all of the involved areas. Conclusions: This international process resulted in consensus for updated EGID nomenclature for both clinical and research use. EGID will be the umbrella term, rather than “eosinophilic gastroenteritis,” and specific naming conventions by location of GI tract involvement are recommended. As more data are developed, this framework can be updated to reflect best practices and the underlying science.]]> Wed 24 May 2023 11:40:45 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42216 Wed 22 Mar 2023 15:44:59 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12769 Sat 24 Mar 2018 08:18:19 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12781 90% decrease in mean eosinophil count) was observed in 11 of 15 subjects who received 6 weeks of fluticasone (62%), compared with none of the 15 subjects who received placebo (P < .001), based on intention-to-treat analysis; histologic responses were observed in 68% of subjects who received fluticasone (13 of 19) compared with none of those who received placebo (0 of 15) by per-protocol analysis (P < .001). Intracellular staining for eosinophil-derived neurotoxin was reduced in 81% of subjects who received fluticasone (13 of 16) compared with 8% who received placebo (1 of 13) (P < .001). Dysphagia was reduced in 57% of subjects who received fluticasone (12 of 21) compared with 33% who received placebo (7 of 21) (P = .22) by intention-to-treat analysis; dysphagia was reduced in 63% of patients who received fluticasone (12 of 19) and 47% of those who received placebo (7 of 15) (P = .49) based on per-protocol analysis. Esophageal candidiasis developed in 26% of subjects who received fluticasone (5 of 19), but in none of the subjects in the placebo group (P = .05). Aerosolized, swallowed fluticasone leads to a histologic but not a symptomatic response in adults with EoE.]]> Sat 24 Mar 2018 08:18:19 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12380 Sat 24 Mar 2018 08:18:00 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12433 Sat 24 Mar 2018 08:15:28 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26864 4 aeroallergens in 47 % (33/70) and reactions to any food allergen in 63 % (50/80) of patients. There was no evidence of monthly concentration of symptomatic esophageal eosinophilia diagnosis in the subgroups of patients with any positive aeroallergen, >4 positive aeroallergens, or history of atopy. The diagnosis of symptomatic esophageal eosinophilia is not made more frequently in the summer months.]]> Sat 24 Mar 2018 07:41:45 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44768 Fri 05 Jul 2024 09:05:53 AEST ]]>